A phase 1/2, Multicenter, Open-Label, Dose-escalation study of AG-221 in subjects with advanced solid tumors, Including glioma, and With Angioimmunoblastic T-cell lymphoma, That harbor an IDH2 mutation. This evidence concerns the gene IDH2 and glioma.